Publications by authors named "G Gourzoulidis"
Background/objectives: To evaluate the health benefits, costs, and cost-effectiveness of vaccination with bivalent respiratory syncytial virus stabilized prefusion F vaccine (RSVpreF) for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in Greek adults 60 years of age and older.
Methods: A Markov model was adapted to simulate lifetime risk of health and economic outcomes from the public payer's perspective over a lifetime horizon. Epidemiology, vaccine effectiveness, utilities, and direct medical costs (EUR, 2024) were obtained from published studies, official sources, and local experts.
Article Synopsis
- Ankylosing spondylitis is a chronic inflammatory disease affecting the spine and quality of life, and this study aimed to compare the cost-effectiveness of tofacitinib with existing biologic treatments in Greece for patients not responding to traditional therapies.
- The analysis utilized a decision tree and a Markov model to evaluate treatment effectiveness by measuring patient outcomes like disease activity and functional score improvements while considering treatment costs and potential adverse effects.
- Results indicated that tofacitinib may offer increased quality-adjusted life-years compared to adalimumab in patients who are new to biologic therapies, potentially leading to a more favorable cost-effectiveness profile.
Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece.
Expert Rev Pharmacoecon Outcomes Res
March 2024
Objectives: To evaluate the cost-effectiveness of lorlatinib compared to 1 generation anaplastic lymphoma kinase (ALK) TKI crizotinib, and 2 generation TKIs alectinib and brigatinib, for previously untreated patients with ALK+ advanced Non-Small Cell Lung Cancer (aNSCLC).
Methods: A partitioned survival model was locally adapted from a Greek payer perspective over a lifetime horizon. Clinical, safety and utility data were extracted from literature.
Background: Specialized occupational health and safety (OHS) issues are covered at the EU level through detailed legislation and guidelines. Unfortunately, this does not extend to occupational heat stress, not only in Greece but also (with few exceptions) internationally. One possible explanation could be the difficulty in accurately identifying the dangerous conditions, as many environmental and individualized elements are involved, and hundreds of "thermal stress indicators" are available.
View Article and Find Full Text PDFObjective: Higher valency pneumococcal conjugate vaccines (PCVs) are expected to improve protection against pneumococcal disease through coverage of additional serotypes. The aim of the present study was to evaluate the cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) compared to 15-valent pneumococcal conjugate vaccine (PCV15) alone or followed by 23-valent polysaccharide vaccine (PPV23) for adults in Greece.
Methods: A published Markov model was adapted to simulate lifetime risk of clinical and economic outcomes from the public payer's perspective.